Is It Time To Reassess ImmunityBio (IBRX) After Its Recent Share Price Surge
- If you are wondering whether ImmunityBio’s current share price really reflects its potential, you are not alone. This article focuses on what the numbers suggest about value rather than short term excitement.
- The stock closed at US$8.45 most recently, with returns of 39.7% over 30 days, 318.3% year to date and 190.4% over 1 year, although the last 7 days saw a 19.1% decline and the 5 year return sits at a 72.6% loss.
- These swings have come alongside ongoing interest in ImmunityBio’s pipeline and regulatory progress, with recent headlines keeping attention on how its clinical developments could affect long term prospects. That backdrop helps explain why sentiment around the stock has been shifting so quickly, even without focusing on…
Source link
